---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Natural history, survival, and mortality"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Natural history, survival, and mortality. Topics: Age-related rise in blood pressure, Blood pressure and vascular mortality: one million adults in 61 prospective studies, US mortality attributed to high blood pressure, Global mortality, and 8 further topics. 12 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Age-related rise in blood pressure

> “With aging, population SBP levels tend to rise steadily to the end of life, whereas DBP levels rise until the fifth decade of life, plateau for a decade, and decline thereafter.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.3-2"></a>

### Blood pressure and vascular mortality: one million adults in 61 prospective studies

> “At ages 40-69 years, each difference of 20 mm Hg usual SBP (or, approximately equivalently, 10 mm Hg usual DBP) is associated with more than a twofold difference in the stroke death rate, and with twofold differences in the death rates from IHD and from other vascular causes.”
> “Throughout middle and old age, usual blood pressure is strongly and directly related to vascular (and overall) mortality, without any evidence of a threshold down to at least 115/75 mm Hg.”

Source: [Lewington et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12493255/)

> “Meta-analyses of observational studies have demonstrated that elevated BP and hypertension are associated with a higher risk of CVD, end-stage kidney disease, subclinical atherosclerosis, and all-cause death.”
> “Hypertension is the most prevalent modifiable CVD risk factor and is the leading cause of death and disability worldwide, with an increasing burden over the last several decades.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.3-3"></a>

### US mortality attributed to high blood pressure

> “In 2024, high blood pressure was a primary or contributing cause of 680,179 deaths in the United States”

Source: [CDC High Blood Pressure Facts (2026)](https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html)

> “The 2022 age-adjusted death rate attributable primarily to HBP was 31.5 per 100 000.”
> “From 2012 to 2022, the age-adjusted death rate attributable to HBP increased 63.2%, and the actual number of deaths attributable to HBP rose 93.0%.”
> “When any mention of HBP was present, the overall age-adjusted death rate in 2022 was 163.1 per 100 000.”

Source: [Martin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12256702/)

<a id="topic-2.2.1.3-4"></a>

### Global mortality

> “Hypertension is a major cause of premature death worldwide.”

Source: [World Health Organization hypertension fact sheet (2025)](https://www.who.int/news-room/fact-sheets/detail/hypertension)

<a id="topic-2.2.1.3-5"></a>

### Hypertensive emergency: in-hospital and one-year outcomes

> “Patients with hypertensive emergencies experience a high in-hospital mortality rate of 10% with a 1-year cardiovascular morbidity and mortality rate of 20% to 30%.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.3-6"></a>

### Resistant hypertension prognosis: guideline statements

> “Patients with resistant hypertension are known to have at least a 50% higher risk of MI, stroke, end-stage kidney disease, and cardiovascular death than adults with hypertension without resistance to treatment.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Compared with treated patients who achieve BP control, patients with resistant hypertension (by any definition) have a worse prognosis: risk of myocardial infarction, stroke, end-stage renal disease, and death in these adults may be two- to six-fold higher.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

> “Importantly, it has been demonstrated that patients with resistant hypertension are at a higher risk of end-organ damage and have a nearly 50% greater risk for cardiovascular events and mortality as compared to those with non-resistant disease.”

Source: [Earle et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488949/)

<a id="topic-2.2.1.3-7"></a>

### Resistant hypertension prognosis: incident treated hypertension in two US health plans

> “Over 3.8 years of median follow-up, cardiovascular event rates were significantly higher in those with resistant hypertension (unadjusted: 18.0% vs. 13.5%, p<0.001). After adjusting for patient and clinical characteristics, resistant hypertension was associated with a higher risk of cardiovascular events (HR 1.47, 95% CI 1.33–1.62).”

Source: [Daugherty et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/)

<a id="topic-2.2.1.3-8"></a>

### Resistant hypertension prognosis: renal, cardiovascular, and mortality outcomes in 470,386 individuals

> “Resistant hypertension (cRH and uRH) compared to non-RH, had multivariable adjusted hazard ratios (95% confidence intervals) of 1.32 (1.27–1.37), 1.24 (1.20–1.28), 1.46 (1.40–1.52), 1.14 (1.10–1.19), and 1.06 (1.03–1.08) for ESRD, IHE, CHF, CVA, and mortality, respectively.”
> “The risk of ESRD and CVA and were 25% and 23% greater, respectively, in uRH compared to cRH supporting the linkage between blood pressure and both outcomes.”

Source: [Sim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4556588/)

<a id="topic-2.2.1.3-9"></a>

### Resistant hypertension prognosis: ambulatory confirmation and mortality, Spanish ABPM registry

> “Compared with controlled hypertension, resistant hypertension was associated with an increased risk in all-cause (HR, 1.21 [95% CI, 1.12-1.30]) and cardiovascular mortalities (HR, 1.33 [95% CI, 1.17-1.51]) in confounder-adjusted models.”
> “When ABPM-confirmed and white-coat resistant hypertension were separately compared with controlled hypertension, only the former was associated with an increased risk of death and cardiovascular death (HR, 1.36 [95% CI, 1.26-1.48] and 1.56 [95% CI, 1.36-1.79]), respectively.”

Source: [de la Sierra et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39247961/)

<a id="topic-2.2.1.3-10"></a>

### Resistant hypertension prognosis: Thai hospital cohort

> “Regarding the prognosis of aRHT, compared to non-aRHT patients, those with aRHT had significant higher risk of CAD, CKD, HF, and all-cause mortality with hazard ratios (95% CI) of 1.80 (1.56–2.08), 1.93 (1.79–2.08), 4.24 (3.54–5.08), and 2.84 (1.89–4.27), respectively.”

Source: [Teza et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875774/)

<a id="topic-2.2.1.3-11"></a>

### Effect of blood pressure control within resistant hypertension

> “Prospective studies using ABPM have suggested an almost 2-fold increased risk of CVD events in patients with true RH compared with those with hypertension responsive to treatment.”
> “BP control reduced the risk of incident stroke, coronary heart disease, or heart failure by 13% among those with RH compared with a 31% lower risk of these outcomes among patients without RH.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

<a id="topic-2.2.1.3-12"></a>

### Mortality with hypertension uncontrolled on two or more medications: company statement

> “Patients with hypertension that persists despite taking two or more medications have 1.8 and 2.5 times greater mortality risk due to either cardiovascular disease or stroke, respectively.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
